Stock Track | Bionano Genomics Plunges on Weak Q3 Revenue Outlook

Stock Track

2024-10-10

Shares of Bionano Genomics (NASDAQ: BNGO) plummeted by 5.42% on Tuesday after the company lowered its revenue guidance for the third quarter of 2024.

The genomic analysis company now expects revenue for Q3 2024 to range between $6.5 million and $6.8 million, down significantly from its previous guidance of $7.9 million to $8.9 million. The revised outlook also fell short of the consensus estimate of $7.85 million.

In a press release, Bionano CEO Erik Holmlin cited a strategic shift toward driving utilization of its optical genome mapping (OGM) technology among existing customers rather than emphasizing new system placements. He also acknowledged headwinds experienced in the capital equipment sector, which likely impacted the company's ability to sell new OGM systems during the quarter.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1144253749"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1144253749\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1144253749?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-10 21:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144253749","market":"us","top_or_hot":-1,"title":"Stock Track | Bionano Genomics Plunges on Weak Q3 Revenue Outlook","media":"Stock Track","content":"<html><body><p>Shares of Bionano Genomics (NASDAQ: BNGO) plummeted by 5.42% on Tuesday after the company lowered its revenue guidance for the third quarter of 2024.</p>\n<p>The genomic analysis company now expects revenue for Q3 2024 to range between $6.5 million and $6.8 million, down significantly from its previous guidance of $7.9 million to $8.9 million. The revised outlook also fell short of the consensus estimate of $7.85 million.</p>\n<p>In a press release, Bionano CEO Erik Holmlin cited a strategic shift toward driving utilization of its optical genome mapping (OGM) technology among existing customers rather than emphasizing new system placements. He also acknowledged headwinds experienced in the capital equipment sector, which likely impacted the company's ability to sell new OGM systems during the quarter.</p></body></html>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Stock Track | Bionano Genomics Plunges on Weak Q3 Revenue Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Bionano Genomics Plunges on Weak Q3 Revenue Outlook\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-10-10 21:58</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Shares of Bionano Genomics (NASDAQ: BNGO) plummeted by 5.42% on Tuesday after the company lowered its revenue guidance for the third quarter of 2024.</p>\n<p>The genomic analysis company now expects revenue for Q3 2024 to range between $6.5 million and $6.8 million, down significantly from its previous guidance of $7.9 million to $8.9 million. The revised outlook also fell short of the consensus estimate of $7.85 million.</p>\n<p>In a press release, Bionano CEO Erik Holmlin cited a strategic shift toward driving utilization of its optical genome mapping (OGM) technology among existing customers rather than emphasizing new system placements. He also acknowledged headwinds experienced in the capital equipment sector, which likely impacted the company's ability to sell new OGM systems during the quarter.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNGO","symbol_name":"Bionano Genomics","start_time":0,"source_url":"","article_id":"1144253749","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144253749","pubTimestamp":1728568716,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Bionano Genomics  plummeted by 5.42% on Tuesday after the company lowered its revenue guidance for the third quarter of 2024.The genomic analysis company now expects revenue for Q3 2024 to range between $6.5 million and $6.8 million, down significantly from its previous guidance of $7.9 million to $8.9 million. The revised outlook also fell short of the consensus estimate of $7.85 million.In a press release, Bionano CEO Erik Holmlin cited a strategic shift toward driving utilization of","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BNGO":"Bionano Genomics"},"translate_title":"股票赛道Bionano Genomics因第三季度收入前景疲软而暴跌","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNGO":1},"content_text":"Shares of Bionano Genomics (NASDAQ: BNGO) plummeted by 5.42% on Tuesday after the company lowered its revenue guidance for the third quarter of 2024.\nThe genomic analysis company now expects revenue for Q3 2024 to range between $6.5 million and $6.8 million, down significantly from its previous guidance of $7.9 million to $8.9 million. The revised outlook also fell short of the consensus estimate of $7.85 million.\nIn a press release, Bionano CEO Erik Holmlin cited a strategic shift toward driving utilization of its optical genome mapping (OGM) technology among existing customers rather than emphasizing new system placements. He also acknowledged headwinds experienced in the capital equipment sector, which likely impacted the company's ability to sell new OGM systems during the quarter.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1}}}